Model Medicines

United States · Biotech

Model Medicines uses AI to discover and develop small molecule drug candidates targeting biological mechanisms shared across diseases.

Product and customers

Model Medicines develops small molecule drug candidates using an AI platform that supports target discovery, molecular design and preclinical development. Its approach focuses on biological mechanisms that can affect multiple diseases.

Its research programmes include antiviral therapies targeting viral RNA polymerase and therapies targeting the BRD4 transcriptional regulator. The San Diego biotechnology company is advancing investigational compounds through preclinical development.

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Equity offering$5.1MParticipants not disclosed
Sourcesmodelmedicines.com ↗modelmedicines.com ↗